TetraLogic Pharmaceuticals, a US-based developer of anti-cancer drugs backed by pharmaceutical company Pfizer, has raised $6m in its extended series C round from venture capital firm Nextech Invest.
In September, Pfizer through its corporate venturing unit invested $5m in TetraLogic.
Pfizer Ventures’ investment extended TetraLogic’s series C round, which originally closed in August at $32m.
Amgen Ventures, the $100m corporate venturing division of biotech company Amgen, and venture capital firms Clarus Ventures, which led the C round, Hatteras Venture Partners, HealthCare Ventures, Latterell Venture Partners, Novitas Capital, Quaker BioVentures and Vertical Group were the members of August’s investment consortium.
Amgen had originally invested in TetraLogic, a US-based developer of drugs to treat cancer, at its $36m series B round in mid-2006, two years after the corporate venturing division was launched.
However, some of TetraLogic’s original investors from its $8m series A round in 2004, PA Early Stage Partners and Kammerer Associates, were not mentioned by the company as part of the C round.